Summary

Commonly reported side effects of ocrelizumab include: lower respiratory tract infection, upper respiratory tract infection, cough, and infusion related reaction. Continue reading for a comprehensive list of adverse effects.

Applies to ocrelizumab: parenteral concentrate for iv infusion.

Side effects include:

Relapsing forms of MS (≥10%): upper respiratory tract infection and infusion reaction.

PPMS (≥10%): upper respiratory tract infection, infusion reaction, skin infection, and lower respiratory tract infection.

For Healthcare Professionals

Applies to ocrelizumab: intravenous solution.

Respiratory

Very common (10% or more): Upper respiratory tract infection (49%), nasopharyngitis (24%), lower respiratory tract infection (10%)

Common (1% to 10%): Bronchitis, cough^[Ref]

Psychiatric

Common (1% to 10%): Depression^[Ref]

Oncologic

Uncommon (0.1% to 1%): Breast cancer^[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, pain in extremity^[Ref]

Local

Very common (10% or more): Infusion reactions (40%)^[Ref]

Immunologic

Common (1% to 10%): Herpes virus associated infections

Frequency not reported: Immunogenicity^[Ref]

Hematologic

Very common (10% or more): Neutrophil levels decreased (13%)^[Ref]

Dermatologic

Very common (10% or more): Skin infections (14%)^[Ref]

Ocular

Common (1% to 10%): Conjunctivitis^[Ref]

Metabolic

Common (1% to 10%): Peripheral edema^[Ref]